<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <akn:act name="dc-code">
    <akn:meta>
      <akn:identification source="#cosilico">
        <akn:FRBRWork>
          <akn:FRBRuri value="/akn/us-dc/code/48-902.14"/>
          <akn:FRBRdate date="2025-12-31" name="retrieval"/>
          <akn:FRBRauthor href="#dc-council"/>
          <akn:FRBRcountry value="us-dc"/>
        </akn:FRBRWork>
        <akn:FRBRExpression>
          <akn:FRBRuri value="/akn/us-dc/code/48-902.14/eng@2025"/>
          <akn:FRBRdate date="2025-12-31"/>
          <akn:FRBRauthor href="#cosilico"/>
          <akn:FRBRlanguage language="en"/>
        </akn:FRBRExpression>
      </akn:identification>
    </akn:meta>
    <akn:body>
      <akn:section eId="sec_48_902_14">
        <akn:num>48-902.14</akn:num>
        <akn:heading>Treatment of controlled substance analogues.</akn:heading>
<akn:subsection eId="subsec_48-902_14_a">
      <akn:num>(a)</akn:num>
      <akn:content><akn:p>A controlled substances analogue shall, to the extent intended for human consumption, be treated for the purposes of any District of Columbia law as a controlled substance in Schedule I.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_48-902_14_b">
      <akn:num>(b)</akn:num>
      <akn:content><akn:p>Except as provided in subsection (c) of this section, the term “controlled analogue” means:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_48-902_14_c">
      <akn:num>(c)</akn:num>
      <akn:content><akn:p>Such term does not include:</akn:p></akn:content>
    </akn:subsection>
      </akn:section>
    </akn:body>
  </akn:act>
</akn:akomaNtoso>
